Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1080/20016689.2017.1299665 http://scihub22266oqcxt.onion/10.1080/20016689.2017.1299665 C5405566!5405566!28473888     free     free     free Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 265.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       J+Mark+Access+Health+Policy 2017 ; 5 (1): ä Nephropedia Template TP {{tp|p=28473888|t=2017. Do payers value rarity? An analysis of the relationship between disease rarity and orphan drug prices in Europe |pdf=|usr=}}{{28473888}} gab.com Text Do payers value rarity An analysis of the relationship between disease rarity and orphan drug prices in Europe JO: J Mark Access Health Policy http://www.kidney.de/pget.php?&tw=1&pmid=28473888 #FOAvip Background and Objective: Orphan drugs have been a highlight of discussions due to their higher prices than non-orphan drugs. There is currently no European consensus on the method of value assessment for orphan drugs. This study assessed the relationship between the prevalence of rare diseases and the annual treatment cost of orphan drugs in France, Germany, Italy, Norway, Spain, Sweden, and UK.Methods: Approved orphan drugs and prevalence data were extracted from the European Medicines Agency website. Annual treatment costs were calculated using ex-factory price. Simple regression was used to analyse the relationship between costs and prevalence. A specific bivariate analysis was performed for the rarest diseases (?1 per 10,000).Results: 120 drugs were analysed. Prevalence ranged from 0.001 to 5 per 10,000 (mean 1.24, median 1). Annual treatment costs per patient ranged from ?755 to ?1,051,956 (mean ?100,000, median ?39,303). Results show a statistically significant inverse correlation between annual treatment cost and disease prevalence in all countries (France: r = ?0.370, p = 0.002; Germany: r = ?0.365, p = 0.002; Italy: r = ?0.340, p = 0.002; Spain: r = ?0.316, p = 0.041; UK: r = ?0.358, p = 0.0004; Sweden: r = ?0.414, p = 0.014; Norway: r = ?0.367, p = 0.002). When analysis was focused on the rarest diseases, a stronger correlation exists in all countries (France: r = ?0.525, Germany: r = ?0.482, Italy: r = ?0.497, Spain: r = ?0.531, UK: r = ?0.436, Sweden: r = ?0.455, Norway: r = ?0.466; all p < 0.05 except Sweden p = 0.077).Conclusions: This study shows an inverse correlation between annual treatment cost and prevalence with high statistical significance in the studied countries. Although pricing is a complex process where different attributes are assessed, this study supports the idea that payers value rarity in pricing decisions. Twit Text FOAVip Do payers value rarity An analysis of the relationship between disease rarity and orphan drug prices in Europe ????J Mark Access Health Policy http://www.kidney.de/pget.php?&tw=1&pmid=28473888 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=28473888 #FOAvip English Wikipedia <ref>{{Cite pmid|28473888}}</ref> Do payers value rarity? An analysis of the relationship between disease rarity and orphan drug prices in Europe #MMPMID28473888 Medic G; Korchagina D; Young KE; Toumi M; Postma MJ; Wille M; Hemels M J Mark Access Health Policy 2017[]; 5 (1): ä PMID28473888show ga Background and Objective: Orphan drugs have been a highlight of discussions due to their higher prices than non-orphan drugs. There is currently no European consensus on the method of value assessment for orphan drugs. This study assessed the relationship between the prevalence of rare diseases and the annual treatment cost of orphan drugs in France, Germany, Italy, Norway, Spain, Sweden, and UK.Methods: Approved orphan drugs and prevalence data were extracted from the European Medicines Agency website. Annual treatment costs were calculated using ex-factory price. Simple regression was used to analyse the relationship between costs and prevalence. A specific bivariate analysis was performed for the rarest diseases (?1 per 10,000).Results: 120 drugs were analysed. Prevalence ranged from 0.001 to 5 per 10,000 (mean 1.24, median 1). Annual treatment costs per patient ranged from ?755 to ?1,051,956 (mean ?100,000, median ?39,303). Results show a statistically significant inverse correlation between annual treatment cost and disease prevalence in all countries (France: r = ?0.370, p = 0.002; Germany: r = ?0.365, p = 0.002; Italy: r = ?0.340, p = 0.002; Spain: r = ?0.316, p = 0.041; UK: r = ?0.358, p = 0.0004; Sweden: r = ?0.414, p = 0.014; Norway: r = ?0.367, p = 0.002). When analysis was focused on the rarest diseases, a stronger correlation exists in all countries (France: r = ?0.525, Germany: r = ?0.482, Italy: r = ?0.497, Spain: r = ?0.531, UK: r = ?0.436, Sweden: r = ?0.455, Norway: r = ?0.466; all p < 0.05 except Sweden p = 0.077).Conclusions: This study shows an inverse correlation between annual treatment cost and prevalence with high statistical significance in the studied countries. Although pricing is a complex process where different attributes are assessed, this study supports the idea that payers value rarity in pricing decisions. äDo payers value rarity? An analysis of the relationship between diseas(epmc).pdf DeepDyve Pubget Overpricing